B-Cell Maturation Antigen (BCMA) Targeted Therapies Industry Growth Expected to Reach $36.66 Billion by 2029 at a CAGR of 24.6% | Segmentation and Growth Opportunities
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth in 2025?
The market size for therapies targeting the B-cell maturation antigen (BCMA) have seen significant growth in the past few years. The market value is projected to increase from $12.17 billion in 2024 to $15.21 billion in 2025, indicating a compound annual growth rate (CAGR) of 25.0%. Factors such as the increasing attention to hematologic malignancies, a marked increase in oncology research funding, a growing need for personalised medicine, greater acceptance of CAR-T cell therapies, and a rise in healthcare expenditure have all contributed to the growth during the historical period.
What Is the Forecast for the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Through 2029?
In the coming years, exponential growth is anticipated for the B-cell maturation antigen (BCMA) targeted therapies market, with an expected value of $36.66 billion in 2029 and a compound annual growth rate (CAGR) of 24.6%. The expected growth in this period is due to an increasing emphasis on cancer research, the shift towards targeting specific molecular markers, the prevalence of cancers, a rise in biotech investments, and a growing adoption of cell and gene therapies. The forecast period is also likely to see significant trends such as the application of CRISPR technology, advancements in gene-editing techniques, developments in next-generation car-t cell therapies, progress in targeted antibody-drug conjugates, and the creation of off-the-shelf treatments.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20718&type=smp
What are the Key Market Players in B-Cell Maturation Antigen (BCMA) Targeted Therapies Market and How They’re Evolving?
Major companies operating in the B-cell maturation antigen (BCMA) targeted therapies market are Bristol Myers Squibb Company, Novartis, GlaxoSmithKline (GSK), Takeda Pharmaceutical Company Limited, Amgen Inc, Regeneron Pharmaceuticals, Beigene, Arcellx Inc, Poseida Therapeutics, Legend Biotech Corporation, Cartesian Therapeutics, Juno Therapeutics, Sutro Biopharma Inc, CARsgen Therapeutics, Precision BioSciences, Eureka Therapeutics Inc, Cellectis, Teneobio Inc., Janssen Pharmaceuticals Companies, Allogene Therapeutics, Affimed, Bluebird Bio Inc.
What Are the Primary Growth Drivers in the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?
The increasing occurrences of multiple myeloma are anticipated to stimulate the advancement of the b-cell maturation antigen (BCMA) targeted therapies market. Multiple myeloma, a cancer variant that primarily impacts plasma cells, essential elements of the immune system for antibody production, is increasing due to several contributing factors. These include a global aging population, enhanced diagnostic abilities, and disparities in healthcare availability. BCMA targeted therapies play a vital role in managing multiple myeloma by focusing on and removing harmful plasma cells that express BCMA, proposing a promising method for more efficient and precise treatment. For example, in August 2024, the American Cancer Society announced that there were roughly 35,780 fresh instances of multiple myeloma discovered in the United States, incorporating 19,520 amongst men and 16,260 amongst women. Moreover, approximately 12,540 fatalities were foreseen, consisting of 7,020 men and 5,520 women. Hence, the escalating prevalence of multiple myeloma is fuelling the growth in the b-cell maturation antigen (BCMA) targeted therapies market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=20718&type=smp
What Are the Leading Segments in the Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Industry?
The B-cell maturation antigen (BCMA) targeted therapies market covered in this report is segmented –
1) By Product Type: Antibody Drug Conjugates, Chimeric Antigen Receptor T (CAR-T)-Cell Therapy, Bispecific Antibodies
2) By Indication Type: Acute Lymphoblastic Leukemia, Multiple Myeloma
3) By End User: Hospitals, Specialty Clinics, Home Care Settings
Subsegments:
1) By Antibody Drug Conjugates: BCMA-Targeted ADCs (Antibody-Drug Conjugates), Linker-Payload Technology-Based BCMA ADCs
2) By Chimeric Antigen Receptor T (CAR-T)-Cell Therapy: BCMA CAR-T Cells (Autologous), Allogeneic BCMA CAR-T Cells
3) By Bispecific Antibodies: BCMA x CD3 Bispecific Antibodies, BCMA x CD28 Bispecific Antibodies
What Are the Key Market Trends in the B-Cell Maturation Antigen (BCMA) Targeted Therapies Industry?
Prominent businesses in the BCMA-targeted therapies market are concentrating their efforts on the development of novel treatments such as CAR-T cell therapy, with the aim of improving the accuracy and potency of cancer cell targeting. CAR-T cell therapy is a form of immunotherapy where a patient’s T cells are altered to express chimeric antigen receptors (CARs), which are designed to seek out and destroy cancer cells. For example, in April 2024, Johnson & Johnson, an American pharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for CARVYKTI. CARVYKTI (ciltacabtagene autoleucel) is an immune therapy that uses genetically modified autologous T cells to target BCMA. It is designed for use in adult patients suffering from relapsed or refractory multiple myeloma who have tried at least one other treatment and are resistant to lenalidomide.
Access The Full Report Here:
What Is the Regional Outlook for the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?
North America was the largest region in the B-cell maturation antigen (BCMA) targeted therapies market in 2024. The regions covered in the B-cell maturation antigen (BCMA) targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20718
This Report Delivers Insight On:
1. How big is the b-cell maturation antigen (bcma) targeted therapies market, and how is it changing globally?
2. Who are the major companies in the b-cell maturation antigen (bcma) targeted therapies market, and how are they performing?
3. What are the key opportunities and risks in the b-cell maturation antigen (bcma) targeted therapies market right now?
4. Which products or customer segments are growing the most in the b-cell maturation antigen (bcma) targeted therapies market?
5. What factors are helping or slowing down the growth of the b-cell maturation antigen (bcma) targeted therapies market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
